Monoclonal Anti-PD-L1 Antibody, Mouse IgG1 (1G1)
抗PD-L1單克隆抗體
描述/背景（Background）
Programmed death ligand 1 (PD-L1) is the principal ligand of programmed death 1 (PD-1), a coinhibitory receptor that can be constitutively expressed or induced in myeloid, lymphoid, normal epithelial cells and in cancer. A key immune checkpoint is triggered when PD-1 (programmed cell death protein 1) engages its ligand PD-L1. As a result of this interaction, T cell activation is attenuated and an active immune response is prevented.
This mechanism is often co-opted by tumors. PD-L1 is upregulated in several tumor types and contributes to the malignancy of these cancers by interacting with PD-1 and inhibiting T cell activation. In this way, the tumors avoid detection and destruction by the immune system. Accordingly, PD-1 and PD-L1 have garnered much attention for their roles in tumor immunology and as immune-based therapeutic targets.
種屬（Host Species）
Mouse
克隆號（Clone）
1G1
適用方法（Application）
IHC
效價(jià)（Property）
1：500
狀態(tài)（State）
Liquid
陽性對照（Positive Control）
Human Tonsil Tissues
克隆類型（Clonality）
Monoclonal
分子別名（Synonym）
PDL1, PD-L1, CD274, B7-H1, B7H1
研究領(lǐng)域（Research Field）
Cancer Drug Targets
抗體來源（Source）
Mouse
同種型（Isotype）
IgG
儲(chǔ)存（Storage）
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle.
典型數(shù)據(jù)（Typical Data）
用戶評價(jià)：
關(guān)鍵字： PD-L1單克隆抗體;PD-L1;Anti-PD-L1;PD-L1 Antibody;PD-L1抗體;
百普賽斯集團(tuán)ACROBiosystems Group（股票代碼：301080）是成立于2010年的跨國生物科技公司，是為全球生物醫(yī)藥、健康產(chǎn)業(yè)領(lǐng)域提供關(guān)鍵生物試劑產(chǎn)品及解決方案的行業(yè)平臺(tái)型基石企業(yè)。2021年在創(chuàng)業(yè)板上市。百普賽斯集團(tuán)業(yè)務(wù)遍布全球，橫跨亞洲、北美洲、歐洲，在中國、美國、瑞士等12個(gè)城市設(shè)有辦公室、研發(fā)中心及生產(chǎn)基地。目前累計(jì)服務(wù)客戶超6000家，與全球Top 20醫(yī)藥企業(yè)均建立了長期、穩(wěn)定的合作伙伴關(guān)系。集團(tuán)旗下?lián)碛衅放艫CROBiosystems百普賽斯、bioSeedin柏思薈、Condense Capital墾拓資本和ACRODiagnostics百斯醫(yī)學(xué)等。